Pulmonary squamous cell carcinoma with COPD
Conditions
Interventions
Exposed group:Type 2 inflammation
Control group:Non-type 2 inflammation
Sponsors
Army Medical Center of PLA
Eligibility
Sex/Gender
All
Age
40 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. Age 40–80 years, diagnosed with unresectable Stage IIIA–IIIC or Stage IV pulmonary squamous cell carcinoma following combination chemoimmunotherapy (with or without concurrent or sequential radiotherapy); 2. Concurrent diagnosis of COPD (diagnostic criteria according to GOLD 2024); 3. Further stratified into a type 2 inflammation group and a non-type 2 inflammation group based on the definition of type 2 inflammatory response (blood eosinophil count >=300 cells/µL).
Exclusion criteria
Exclusion criteria: 1. History of asthma; 2. Exclusion of other pulmonary, extrapulmonary, or systemic diseases associated with elevated eosinophil counts.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Progression-Free Survival;Tumor response assessment (imaging, tumor markers);Overall Survival;Clinical efficacy assessment (including complete response, partial response, stable disease, and progressive disease); | — |
Countries
China
Contacts
Public ContactLi Li
Army Medical Center of PLA
Outcome results
None listed